Historical Valuation
Immunovant Inc (IMVT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.35. The fair price of Immunovant Inc (IMVT) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：26.18
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Immunovant Inc (IMVT) has a current Price-to-Book (P/B) ratio of 8.70. Compared to its 3-year average P/B ratio of 8.13 , the current P/B ratio is approximately 6.99% higher. Relative to its 5-year average P/B ratio of 5.88, the current P/B ratio is about 47.89% higher. Immunovant Inc (IMVT) has a Forward Free Cash Flow (FCF) yield of approximately -8.21%. Compared to its 3-year average FCF yield of -7.92%, the current FCF yield is approximately 3.69% lower. Relative to its 5-year average FCF yield of -9.86% , the current FCF yield is about -16.68% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for IMVT competitors is 225.08, providing a benchmark for relative valuation. Immunovant Inc Corp (IMVT.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of IMVT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IMVT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IMVT currently overvalued or undervalued?
Immunovant Inc (IMVT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.35. The fair price of Immunovant Inc (IMVT) is between to according to relative valuation methord.
What is Immunovant Inc (IMVT) fair value?
IMVT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Immunovant Inc (IMVT) is between to according to relative valuation methord.
How does IMVT's valuation metrics compare to the industry average?
The average P/S ratio for IMVT's competitors is 225.08, providing a benchmark for relative valuation. Immunovant Inc Corp (IMVT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Immunovant Inc (IMVT) as of Jan 14 2026?
As of Jan 14 2026, Immunovant Inc (IMVT) has a P/B ratio of 8.70. This indicates that the market values IMVT at 8.70 times its book value.
What is the current FCF Yield for Immunovant Inc (IMVT) as of Jan 14 2026?
As of Jan 14 2026, Immunovant Inc (IMVT) has a FCF Yield of -8.21%. This means that for every dollar of Immunovant Inc’s market capitalization, the company generates -8.21 cents in free cash flow.
What is the current Forward P/E ratio for Immunovant Inc (IMVT) as of Jan 14 2026?
As of Jan 14 2026, Immunovant Inc (IMVT) has a Forward P/E ratio of -8.61. This means the market is willing to pay $-8.61 for every dollar of Immunovant Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Immunovant Inc (IMVT) as of Jan 14 2026?
As of Jan 14 2026, Immunovant Inc (IMVT) has a Forward P/S ratio of 0.00. This means the market is valuing IMVT at $0.00 for every dollar of expected revenue over the next 12 months.